RxDoctor Payments Data

Whitney Gawronski, APRN

Family · Swanton, OHNPI 1417522319

Payments from drug & device makers

$3,145in general payments, 2019–2025

Across 174 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$812
  • Novo Nordisk$447
  • Corcept Therapeutics$354
  • Otsuka America Pharmaceutical, Inc.$209
  • Pfizer$182
  • Exact Sciences$98
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,145100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,145 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$15,112
Medicare patients
87
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$39,859
TrulicityDulaglutide25$22,954
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,162
DuleraMometasone/Formoterol16$5,596
Albuterol Sulfate HfaAlbuterol Sulfate80$3,161
Gabapentin104$2,477
Atorvastatin Calcium206$2,309
Buspirone Hcl40$1,533
Omeprazole79$1,000
Metoprolol Succinate61$942
Mirtazapine13$864
Losartan Potassium59$772
Levothyroxine Sodium72$761
Pantoprazole Sodium50$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$447$39,85925 claims
Lilly USA, LLCTrulicity$79$22,95425 claims
AstraZenecaBreztri Aerosphere$50$12,48211 claims
GSKTrelegy Ellipta$90$10,16212 claims
MerckDulera$71$5,59616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Swanton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →